FIELD: medicine. SUBSTANCE: method involves applying thymogen (L-glutamyl-L-triptophane) as diabetes therapy means. EFFECT: enhanced effectiveness of treatment; increased hypoglycemic insulin action; reduced lipid peroxidation level; beta-cells protection. 7 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTIDIABETIC AGENT | 2001 |
|
RU2197259C1 |
ANTIDIABETIC AGENT | 2001 |
|
RU2195300C1 |
MEANS WITH HYPOGLYCEMIC, HYPOLIPIDEMIC AND ENERGY PROTECTIVE EFFECTS | 2016 |
|
RU2630576C1 |
COMPOSITION POSSESSING ANTIDIABETIC ACTION | 2015 |
|
RU2611353C2 |
ANTIDIABETIC COMPOSITION | 2009 |
|
RU2430735C1 |
MEDICATION AND METHOD OF COMPLEX THERAPY OF PATIENTS WITH DIABETES MELLITUS | 2012 |
|
RU2548731C2 |
ANTIDIABETIC AGENT | 1998 |
|
RU2150952C1 |
TETRAPEPTIDE REGULATING GLUCOSE LEVEL IN DIABETES MELLITUS, PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD FOR ITS APPLYING | 2003 |
|
RU2242241C1 |
SUBSTITUTED 4-{[4-(3,3-DIOXIDO-1,3-BENZOXATHIOL-6-YL)ARYLOXY]METHYL}PIPERIDINES AS GPR119 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR PRODUCING AND USING THEM | 2014 |
|
RU2576037C1 |
METHOD FOR SIMULATING ALLOXAN DIABETES | 2013 |
|
RU2534411C1 |
Authors
Dates
2001-04-27—Published
2000-06-09—Filed